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Objective: To describe the diagnostic performance of array comparative genomic hybridization (aCGH) as a
potential first line diagnostic method in first trimester high risk pregnancies.
Method: In a retrospective study we performed aCGH using a targeted array BAC platform (Constitutional ChipW
4.0, PerkinElmer, Turku Finland, median resolution 600 kB) and the Affymetrix CytogeneticsW Whole Genome 2.7 M
array (at a resolution of 400kB) on 100 anonymized prenatal samples from first trimester high risk pregnancies with
normal conventional karyotype. We studied the technical feasibility and turn-around-time as well as the detection
rate of pathogenic submicroscopic chromosome anomalies and CNVs of unknown significance.
Results: We obtained results in 98 of 100 samples in 3 to a maximum of 5 days after DNA extraction. At the given
resolution we did not identify any additional pathogenic CNVs but two CNVs of unknown significance in the
chromosomal regions 1q21.1q21.2 (deletion) and 5p15.33 (duplication) (2%).
Conclusion: In accordance with a growing number of reports this study supports the concept that aCGH at a
resolution of 400-600kB may be used as a first line prenatal diagnostic test with high diagnostic safety and rapid
turn-around time in high-risk first trimester pregnancies. Detection rate of CNVs of unknown significance,
considered as a major hindrance for replacing conventional karyotyping by aCGH, is 2%, but the diagnosis of
additional submicroscopic anomalies in this heterogeneous group of patients seems to be rare.
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The current approach to prenatal diagnosis of chromo-
somal anomalies is a non-invasive risk assessment for tri-
somy 21 and other aneuploidies by first trimester or
integrated risk screening offered to all pregnant women. If
these screening approaches reveal an increased risk stand-
ard chromosome analysis after chorion villous sampling
(CVS) or amniocentesis (AC) is offered for the detection
of numerical or structural chromosome aberrations.* Correspondence: Isabel.Filges@unibas.ch
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reproduction in any medium, provided the orThe current approach of risk screening has signifi-
cantly reduced the number of invasive procedures and
has increased the detection rate at the same time [1,2].
Recently, detection of aneuploidy by using massively
parallel sequencing approaches as well as fetal-specific
DNA-methylation ratio on free fetal DNA in maternal
circulation (so-called non-invasive prenatal diagnosis)
has been successful and appears to have the potential to
replace first trimester screening in the near future [3-8].
In clinical practice, however, pregnancies at high risk
for aneuploidy for various reasons do not infrequently
show a normal conventional chromosome analysis. The
limited clinical information provided by the ultrasound
image of the fetal anatomy and physical development
does usually not allow the diagnosis of a specific disease
to be confirmed by appropriate testing which leavestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Distribution of sample types used in this study





Amniocentesis Cultured amniocytes 13
others Pleural liquid 1
Total 100
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dition with developmental delay and/or mental retard-
ation of unknown severity or opting for a termination of
the pregnancy.
Array comparative genomic hybridization (aCGH),
which can provide a much higher resolution than con-
ventional karyotyping, has now become the genetic test
of first choice for postnatal investigation of intellectual
disability (ID) and/or multiple congenital anomalies
(MCA) detecting causal submicroscopic chromosomal
imbalances i.e. microdeletion- and microduplication syn-
dromes in 10-20% in these groups of patients [9,10]. A
limited number of prenatal studies using array based
methods have been conducted on fetuses with normal
karyotypes focusing on high risk for aneuploidy defined
by ultrasound anomalies [11-14] showing variable detec-
tion rates superior to conventional cytogenetics. Still,
important questions are unanswered as to the appropri-
ate platform and resolution, clinical indications, detec-
tion rate for pathogenic imbalances and copy number
variations with unknown significance as well as cost-
benefit and standardisation aspects in particular to the
necessary follow-up studies by conventional karyotyping
and/or fluorescence-in-situ hybridization (FISH) [15,16].
In particular, CNVs of unknown clinical significance are
considered to be the major hindrance of introducing
array-based technologies into prenatal diagnosis as a
first-line approach. Therefore at present, array diagnosis
has only been proposed as an adjunct tool in the investi-
gation of pregnancies with congenital anomalies and
normal karyotype [17].
The significant advances in earlier screening and diag-
nostic testing for genetic disorders have shifted prenatal
diagnosis from screening and diagnosis form the second
trimester to the first trimester. In experienced tertiary
ultrasound centers, the detection rate of fetal structural
anomalies is as high as 40% in the first trimester ultra-
sound [18]. As first trimester screening aims to provide
early diagnosis we consider chorionic villi sampling as
the invasive method of choice. Array-based methods
have the potential to significantly reduce the turn-
around time and replace rapid testing by interphase
FISH, QF-PCR or MLPA. aCGH on chorionic villi could
offer a time-saving and early approach to a comprehen-
sive and high resolution assessment of chromosomal ab-
normalities following first trimester risk screening.
Between May 2009 and January 2011 we conducted a
retrospective study in our tertiary antenatal referral cen-
ter with a high proportion of high risk pregnancies ap-
plying array analysis for pregnancies at high risk for
chromosomal anomalies in the first trimester. As a
standard of care in our center CVS is offered to women
with a confirmed high risk first trimester pregnancy
allowing a comprehensive low resolution karyotype in a24 h direct preparation followed by a conventional
karyotype from cultured cells. Amniocentesis for the
same indication is performed when CVS cannot be con-
sidered for obstetrical reasons or because of patients’
personal preferences. We used aCGH on anonymized
cryopreserved stored or remaining tissue from prenatal
invasive testing from pregnancies at a high risk for
chromosomal anomalies and normal karyotype. Details
on analyzed tissues are given in Table 1. High risk was
defined as a high risk in first trimester screening (1:10 or
higher) or nuchal translucency > 3 mm or both, intra-
uterine growth retardation and/or fetal malformation(s).
Data on the clinical indication for prenatal invasive diag-
nosis, karyotype result, tissue and DNA quality as well
as results of aCGH analysis including pathogenic CNVs
not detected by conventional chromosome analysis as
well as CNVs of unknown significance were collected.
The goal of our study was to optimize technical
aspects and to evaluate technical feasibility, safety and
the potential of automation of aCGH in first trimester
prenatal diagnosis as a first line test with the ultimate
goal to replace direct preparation of chorionic villi that
is used for rapid testing in our laboratory as well as
other rapid aneuploidy testing methods. In addition de-
tection rates of additional pathogenic variants compared
to the rate of undesirable variants of unknown signifi-
cance were assessed.
Results
After technical optimization of DNA sample quality two
analyzed samples (2%) failed to give interpretable results.
In general, DNA quality of cryopreserved cell cultures, de-
pending also on the period of storage, was lower than
DNA quality of fresh tissue. Preferably, DNA extracted
from direct chorionic tissue was used for analysis. How-
ever, DNA from cultured cells was used when direct villi
were either not available any more or its total amount was
insufficient for additional array analysis. In our retrospect-
ive cohort defined by first trimester high risk for chromo-
somal anomalies and normal conventional chromosome
analysis we did not identify any single additional clear-cut
chromosomal anomaly by using aCGH. Detection rate of
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found in the chromosomal region 1q21.1q21.2 (CVS sam-
ple) not overlapping with the recurrent 1q21.1 deletion
syndrome and another CNV (CVS sample) was identified
in the cri-du-chat critical region, but represented a dupli-
cation to which thus far no phenotype is attributed
(Table 2). aCGH provided additional information on the
extent of the aberrations for two CVS samples for
which conventional karyotyping had revealed structural
chromosomal anomalies. In one fetus with malforma-
tions additional material on the long arm of chromo-
some 20q turned out to be a complete trisomy of 20q
with final karyotype designation 46,XY,der(20)(20pter-
> 20qter::20q11.21- > 20q13.33).arr 20q11.21q13.33(20,06
6,572-49,655,888)x3. A pregnancy with high risk in
first trimester screening but normal ultrasound was
diagnosed with a terminal deletion 9p encompassing
the region 9p24.3p24.2 (199,111-4,401,383; hg18) and
a duplication of 2p25.3p24.3 (19,477-14,322,431; hg18)
allowing more precise genotype-phenotype correlation
particularly for the terminal 9p deletion. The extent
explained a normal ultrasound but implies a high risk
for a global developmental delay [19] and thus allows
a more reliable outcome prediction.
We encountered 3 remarkable situations with mosai-
cism of the fetoplacental unit. The specific issue of pla-
cental mosaicism and its consequences for the
diagnostic accuracy have been addressed separately [20].
Discussion
In our retrospective study we failed to show that the de-
tection rate of aCGH at a median resolution of 600 kb
(400 kb respectively) is superior to conventional
chromosome analysis. The detection rate of CNVs of un-
known significance, discussed as a major hindrance to
the introduction of aCGH in prenatal diagnosis, is at 2%.
Due to the retrospective anonymous design of the study
we were not able to confirm or exclude familial segrega-
tion to further elucidate pathogenicity.
In contrast to the existing reports focusing on detec-
tion rates in pregnancies with fetal malformations mostly
diagnosed by second trimester sonography we dealt withTable 2 Copy number variants of unknown significance
CNV Nr. Type of aberration BAC Clone-ID Genome positio
Hg18Start
End
1 Deletion (2 clones) RP5-998N21 147,596,844-147,7
RP11-196G18 147,976,465-148,1
2 Duplication (4 clones) RP11-20B3 3,055,343-3,213,64
CTD-2012M11 3,558,697-3,712,08pregnancies showing a high risk for chromosomal anom-
alies in the first trimester for heterogeneous clinical rea-
sons. Clinical indications for invasive prenatal testing
were increased nuchal translucency (>3 mm) and/or ele-
vated first trimester test risk in 57, more than a half, of
the referred samples. Recently, Leung et al. reported on
the detection of 4 additional pathogenic submicroscopic
anomalies ranging from 1.2 to 7.9 Mb when using a cus-
tom designed array at a median resolution of 100 kb in a
series of 48 pregnancies with nuchal translucency more
than 3.5 mm [21]. However, 2 of these fetuses had add-
itional sonographic anomalies. Both sample sizes,
Leung’s and our’s, are comparably small and the overall
detection rate of pathogenic CNVs in fetuses with
increased NT seems to be rather low, but might never-
theless require further and larger studies. The progres-
sion or regression of cystic hygroma should probably be
taken into account for phenotype correlations, and other
monogenic disorders such as Noonan or CFC -syndrome
caused by mutations in genes of the RAS-signalling
pathway, seem to be a reasonable differential diagnosis
to consider [22-24] (and personal communication
Yntema H.G. European Society Human Genetics C07.6).
In our approach we have chosen a comparably low
and targeted resolution of a median 600 kb resolution
for the BAC-array in order to avoid CNVs of unknown
clinical significance. In a prenatal setting unknown
CNVs can represent a particular challenge as phenotypic
data are sparse compared to the possibilities of obtaining
phenotypic details on postnatal patients. In addition, the
potential option of pregnancy termination requires a
higher level of interpretation accuracy. Our resolution
might be too cautious especially considering our low de-
tection rate of pathogenic imbalances. Most postnatally
identified pathogenic microdeletion- and duplication
syndromes, however, are caused by pathogenic CNVs
larger than 400 kb [25]. Therefore, a whole genome
resolution of 400 kb should provide a reliable prenatal
diagnosis. After extensive individual counselling diagnos-
tic array analysis is now offered as a diagnostic choice in
high risk pregnancies with fetal malformations and nor-






26,269 0.568 Mb 1q21.1q21.2 Unknown significance,
Not overlapping with the
recurrent deletion in the
1q21.1 syndrome
65,420
2 0.656 Mb 5p15.33 Unknown significance,
Region deleted in
cri-du-chat syndrome4
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of a structural aberration detected by conventional
karyotyping.
D’Amours et al. investigated a series of 49 fetuses with
ultrasound anomalies using custom-designed whole gen-
ome oligo-arrays with different resolutions [26]. Out of 4
clinically significant anomalies, all detected by high reso-
lution arrays, only 1 was smaller than 400 kb, one was
about 700 kb and 2 were potentially detectable by con-
ventional chromosome analysis at sizes of about 8 Mb
and 14 Mb. Recent high resolution array studies using
heterogeneous array designs including BAC-, oligo- and
SNP arrays also focusing on detection rates in fetuses
with congenital malformations [12,27-29] yielded vari-
able detection rates of pathogenic CNVs in 1–3% up to
10% [13], and even up to 16% [14]. However, sizes of the
clinically relevant aberrations were larger than 1 Mb
[12,28,29]. Even in the studies using whole genome SNP-
arrays with a resolution higher than 100 kb clinically
relevant aberrations were mainly in the range of 1 Mb or
more [13] or larger than 500 kb or 1 Mb [14,25] in all
but one case [14]. An overall detection rate of 5-6% also
including chromosomal anomalies detectable by conven-
tional karyotyping was shown in array studies dealing
with samples of heterogeneous clinical indications in-
cluding fetal structural anomalies [12,30,31]. Hillman
et al. concludes an overall detection rate of 3.6% regard-
less of the clinical indication and 5.3% for cases with
ultrasound anomalies in his review and meta-analysis of
this recent heterogeneous literature [32].
Referring to these results we would have expected to
find at least one additional submicrosopic anomaly in
our cohort examined. We focused, however, on pregnan-
cies at risk for chromosomal anomalies as determined
by first trimester screening, which has not been system-
atically considered in previous studies. Our patient co-
hort likely represents heterogeneous clinical indications,
the main group being referred for increased nuchal
translucency and elevated first trimester risk screening,
whereas the proportion of fetuses with congenital mal-
formations is comparatively low. Our results are in ac-
cordance with the findings of Faas et al. (personal
communication, ESHG 2011 P05.32) who did not find
any clinically relevant abnormalities in a cohort of 95
fetal samples with ultrasound anomalies including
increased nuchal translucency when implementing a
strategy for routine array diagnosis in parallel to QF-
PCR. High resolution whole genome arrays may there-
fore be specifically indicated in pregnancies with distinct
fetal ultrasound anomalies or in the precise determin-
ation of rare structural chromosomal anomalies.
Our approach revealed a detection rate of 2% for
CNVs of unknown significance at the given resolution,
confirming that aCGH seems to be a safe approach inthe diagnosis of first trimester pregnancies considered at
high risk for chromosomal anomalies. In our experience
aCGH is technically feasible and reliable as a first-line
diagnostic test for prenatal samples, replacing laborious
direct preparation of CVS as well as other rapid but less
comprehensive testing procedures. We were able to pro-
vide a result in 3 to a maximum of 5 days after DNA ex-
traction offering a superior coverage of pathogenic
aberrations in the genome. Thus, aCGH provides the ad-
vantage to give patients a more complete genome ana-
lysis result in a short turn-around-time. High resolution
arrays may gain further importance as we can expect
that the clinical use of non-invasive diagnosis for com-
mon aneuploidies will increase the proportion of sam-
ples from high risk pregnancies obtained by invasive
diagnosis. However, the appropriate array resolution still
remains a matter of debate and may need to be adapted
to the specific clinical indication and/or parental expec-
tations. These would require a flexible resolution design
of arrays and analysis software as well as the possibility
to analyze one single patient in a (very) short turn-
around time or multiple patients in parallel for diagnos-
tic laboratories. Platforms requiring small initial DNA
amount will be advantageous as the DNA amount from
direct villi or amniocytes will be sufficient to allow array
analysis as compared to time-consuming cell culturing
for DNA extraction. For the time being cell cultures may
be used as a back-up for confirmational FISH-analysis as
well as follow-up of mosaic results if aCGH reveals an
unbalanced structural aberration.
Conclusion
For the future application of aCGH in prenatal diagnosis
we see the potential to use aCGH at a resolution of
400–600 Kb as a first line genetic test including the
replacement of rapid testing methods such as direct
preparation of chorionic villi, interphase-FISH and
DNA-based QF-PCR and MLPA with a high diagnostic
safety and accuracy. Considering results of recent stud-
ies high resolution arrays may be specifically indicated
for pregancies with fetal malformations. So far, prenatal
conventional chromosome analysis has been a rather
standardized procedure, but array diagnosis may put




The study was approved by the local ethics committee
EKBB (Ref.Nr.EK: 62/08).
Samples
After technical optimization and validation of aCGH
platforms by using anonymized samples with known
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of so far 100 prenatal samples from high risk pregnan-
cies as defined in the study design. Of 100 patients 88
samples were included in the anonymized retrospective
study. 12 patients seeked diagnostic testing, 2 of which
had structural anomalies in conventional karyotyping,
which were characterized more precisely by array, and 3
had mosaic results on which we reported in detail previ-
ously [20]. A survey of clinical indications is given in
Table 3.
Conventional chromosome analysis
Conventional chromosome analysis was done on chori-
onic villi according to standard procedures evaluating
numerical chromosome aberrations in direct preparation
of cytotrophoblastic cells (QFQ-banding) and long-term
culture of mesenchymal tissue for numerical and struc-
tural aberrations (GTG-banding, 500 band level). Direct
preparation of chorionic villi allows the separation and
analysis of cells from the mitotically active cytotropho-
blastic layer after 24 hours. Chromosome analysis on
amniotic fluid was performed according to standard
protocols.
DNA extraction
The fetal sample was prepared for aCGH analyses
using either direct genomic DNA from chorionic villi,
DNA obtained from cultured CVS cells or DNA from
amniocyte cultures. DNA for subsequent aCGH was
extracted from 10–20 mg of direct chorionic villi or a
T75 flask cell culture using the Qiagen DNeasy Blood
and Tissue kit (Qiagen Germany Gmbh, Hilden) fol-
lowing the manufacturer’s instructions. DNA from un-
processed and uncultured direct villi represents aTable 3 Clinical indications for invasive prenatal




% of total number of
samples
NT>3 mm 26 26.5








IUGR and malformation 10 10.2
Malformation(s) 21** 21.4
Total 98*** 100
* investigation of 2 mosaic and 1 chromosomal structural anomaly included
** investigation of 1 mosaic result and 1 chromosomal structural anomaly
included.
*** 2 samples failed analysis.mixture of cytotrophoblastic and mesenchymal cell
sources whereas DNA from cultured cells is of mesen-
chymal origin. Due to experiences when studying
aCGH in the presence of fetoplacental mosaicism [20]
initial lysis of chorionic villi by proteinase K was fol-
lowed by collagenase digestion to increase the propor-
tion of DNA from mesenchymal cells. RNase treatment
(RNase A, Qiagen Germany Gmbh, Hilden) was added
to remove the high levels of RNA in these tissue types.
DNA concentration and purity was determined using a
NanoDrop 1000 spectrophotometer (Witec AG, Littau,
Switzerland).
Array comparative genomic hybridization (aCGH)
aCGH was performed on extracted DNA in 95 study sam-
ples using the Constitutional ChipW 4.0 (PerkinElmer,
Turku Finland) BAC platform. Validation analysis was
done on 20 samples with known chromosomal aberra-
tions. The BAC array contains more than 5200 distinct
clones in total with a median probe spacing of 600 kb.
Targeted regions with higher clone density are chromo-
somal regions of interest (>1200 clones), subtelomeric
regions with coverage by more than 900 BAC clones, peri-
centromeric regions with enhanced coverage (>100
clones) and the X-chromosome with near to tiling
coverage for high resolution detection of chromosomal
abnormalities across the X-chromosome. An additional
back-bone of more than 2000 BAC clones provides an
average resolution of less than 1 Mb in non-targeted areas.
Two 2 μg of purified DNA is required for analysis. Label-
ling and hybridization of test and reference DNA was per-
formed according to the manufacturer’s protocols. Test
and reference DNA were labelled by Cy3 and Cy5 with re-
ciprocal labelling reactions and hybridized for 16–18
hours on two independent arrays (dye-swap) which allows
to normalize intensity bias introduced by different dye
properties. Arrays were then subjected to 4 washings
according to the protocol. Two colour scanning was per-
formed by the PerkinElmerW Inc.'s ScanArrayW Micro-
array Scanner. Acquisition of the microarray images was
performed with the ScanArray Express software, Micro-
array Analysis System, version 4.0.0.0004. Data extraction,
analysis and visualisation were done by the Oneclick CGH
software, version 4.3.3., Perkin Elmer Edition. Classifica-
tion of gain and loss was based on the software’s segmen-
tation algorithm with a threshold of a 1.2 ratio (0.26 log2
ratio). A minimum of two consecutive clones indicating
copy number variation was considered as a relevant
aberration.
Due to a technology change in our laboratory the Affy-
metrix CytogeneticsW Whole Genome 2.7 M array,
which is based on 2.7 million copy number markers (CN
markers) and additional 400,000 SNPs (average marker
spacing 1086 bp) was used in further 5 samples for
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postnatal investigation of patients with syndromic and
non-syndromic intellectual disability with an overall
detection rate of pathogenic CNVs of 12.2% in patients
with previously normal karyotype [33]. Validation for
prenatal tissues was performed on 16 control samples.
Only 150 ng of purified DNA is required for analysis
which represents a significant advantage over the 2 μg
required for the BAC array when using prenatal tissues.
Single colour hybridization was performed according to
the manufacturer`s protocol. Arrays were then scanned
by the GeneChip Scanner 3000 7 G system (Affymetrix
Inc. Santa Clara, CA, USA). Results were analyzed by
the Affymetrix Chromosome Analysis Suite (ChASW)
software. Aberrations were filtered by the software up to
a minimal size of 400 kB for deletions and duplications.
Limits were decided based on our own previous experi-
ences and existing literature. Results were reassessed
manually for CNVs.Fluorescence-in-situ hybridization (FISH)
FISH was used for confirmation of dosage imbalances
suspected to be pathogenic in the samples when possible
on remaining tissue culture. Confirmation or exclusion
of involvement in familial rearrangements in parental
samples was not realizable due to the retrospective de-
sign of the study. FISH was performed on metaphase
slides according to the manufacturer’s hybridization pro-
tocols. Clones from Abbott and Kreatech were used
when available for the aberrant region and for control
hybridization. Clones provided by BlueGnome were
chosen within specific regions when the former were not
available.Interpretation of CNV significance
The pathogenicity of the CNVs was assessed using
the guidelines recently discussed [34-37]. All detected
CNVs were compared against the database of gen-
omic variants (http://projects.tcag.ca/variation). If an
aberration was not reported as a benign variant, it
was, in correlation with the phenotype, analyzed for
gene content, function and genomic position poten-
tially in relation to the phenotype or a particular
phenotypic trait, compared with entries in the De-
cipher database (http://decipher.sanger.ac.uk) or Ecar-
uca (www.ecaruca.net) and evaluated against existing
literature for known syndromes and overlapping
causal aberrations. Aberrations likely to be causative
were confirmed by FISH. Aberrations of unknown
significance were documented, however, parental array
analysis was not possible for samples included in the
retrospective testing.Abbreviations
aCGH: Array comparative genomic hybridization; CNV: Copy number variant;
CVS: Chorionic villous sampling; AC: Amniocentesis; ID: Intellectual disability;
MCA: Multiple congenital anomalies; FISH: Fluorescence-in-situ-hybridization.
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